Targacept to Report Third Quarter 2012 Financial Results on November 6, 2012

  Targacept to Report Third Quarter 2012 Financial Results on November 6, 2012

Business Wire

WINSTON-SALEM, N.C. -- November 01, 2012

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics™ , today announced that it will report
financial results for the third quarter of 2012 on Tuesday, November 6, 2012,
after the U.S. financial markets close.

Management will discuss the third quarter financial results, provide an update
on the company’s product development programs and business activities, and
discuss expectations for the future via conference call at 5:00 p.m. Eastern
Time on Tuesday, November 6, 2012. The conference call may be accessed by
dialing 800.706.7741 for domestic participants and 617.614.3471 for
international callers (reference passcode 78046906). A replay of the
conference call may be accessed from approximately 8:00 p.m. Eastern Time on
November 6, 2012 through November 20, 2012 by dialing 888.286.8010 for
domestic callers and 617.801.6888 for international callers (reference
passcode 85901627).

A live audio webcast of the conference call will be accessible from the
Investor Relations page of Targacept’s website, www.targacept.com. To ensure a
timely connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled start time. An archived version of the
webcast will also be available for replay on the Investor Calendar section of
the Investor Relations page of Targacept’s website for at least two weeks
following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for
difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
multiple Phase 2 product candidates, all representing first-in-class
opportunities. Targacept leverages its scientific leadership and diverse
pipeline to attract significant collaborations with global pharmaceutical
companies. For more information, please visit www.targacept.com.

Building Health, Restoring Independence®


Targacept, Inc.
Alan Musso, SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.